<p>在 Google 搜索和 AI 回答中查看更多來自 StockTitan 的信息。將 StockTitan 添加為首選來源 · 打開 Google</p>
<p>在 Google 上添加</p>
<p>Oculis Holding AG（納斯達克：OCS；XICE：OCS）（“Oculis” 或 “公司”）是一家全球生物製藥公司，專注於解決神經眼科和眼科疾病的創新，滿足重大未滿足的醫療需求，今天宣佈 Oculis 管理層將參加第 47 屆高盛全球醫療保健會議的爐邊聊天。</p>
<p>公司將提供其創新的當前晚期產品組合的概述和更新。主要亮點包括：<strong>Privosegtor</strong>，一種新型神經保護候選藥物，已獲得美國食品藥品監督管理局（FDA）的突破性療法認證和歐洲藥品管理局（EMA）的優先藥物（PRIME）認證，用於視神經炎（ON），在 <strong>PIONEER</strong> 註冊項目中，旨在滿足兩種視神經病的未滿足需求，並在美國獨自解鎖超過 70 億美元的潛在市場機會，以及 <strong>Licaminlimab</strong>，一種局部抗 TNFα藥物，正在 <strong>PREDICT-1</strong> 註冊試驗中評估，作為乾眼病（DED）中首個基於基因型的精準醫學。</p>
<p>憑藉強大的資產負債表和先進的產品管線，Oculis 準備在當前資金的支持下交付多個關鍵結果，專注於實現其拯救視力和改善眼科護理的使命，提供突破性治療。</p>
<p><strong>第 47 屆高盛全球醫療保健會議</strong></p>
<p>日期：6 月 9 日，東部時間下午 4:00</p>
<p>地點：佛羅里達州邁阿密</p>
<p>形式：爐邊聊天</p>
<p>演講者：Riad Sherif 博士，首席執行官</p>
<p>網絡直播鏈接：在此註冊</p>
<p>公司將在會議期間提供一對一會議。感興趣的投資者應聯繫其各自的代表，向贊助機構請求會議。</p>
<p>網絡直播鏈接在可用時會發布在 Oculis 網站的投資者與媒體部分的活動與演示頁面上。</p>
<p><strong>-結束-</strong></p>
<p><strong>關於 Oculis</strong></p>
<p>Oculis 是一家全球生物製藥公司（納斯達克：OCS；XICE：OCS），專注於突破性創新，以解決神經眼科和眼科領域中重大未滿足的醫療需求。Oculis 的高度差異化的晚期臨牀管線專注於兩個核心產品候選藥物。Privosegtor 是 PIONEER 項目中的突破性神經保護候選藥物，該項目包括旨在支持視神經病（包括視神經炎（ON）和非動脈性前缺血性視神經病（NAION）治療註冊計劃的研究。Privosegtor 還具有在其他神經眼科和神經疾病中開發額外適應症的潛力。Licaminlimab 是一種新型局部抗 TNFα藥物，正在進行註冊試驗，並採用基因型基礎的方法開發，用於治療乾眼病（DED）患者。Oculis 總部位於瑞士，在美國、冰島和瑞士開展業務，由經驗豐富的管理團隊領導，擁有成功的業績記錄，並得到領先國際醫療投資者的支持。</p>
<p>欲瞭解更多信息，請訪問：www.oculis.com</p>
<p><strong>Oculis 聯繫方式</strong></p>
<p>Sylvia Cheung，首席財務官</p>
<p>sylvia.cheung@oculis.com</p>
<p><strong>投資者關係</strong></p>
<p>LifeSci Advisors</p>
<p>Corey Davis，博士</p>
<p>cdavis@lifesciadvisors.com</p>
<p><strong>媒體關係</strong></p>
<p>ICR Healthcare</p>
<p>Amber Fennell / David Daley / Sean Leous</p>
<p>oculis@icrhealthcare.com</p>
<p><strong>關於前瞻性聲明的警示聲明</strong></p>
<p>本新聞稿包含前瞻性聲明和信息。例如，關於公司產品候選藥物潛在益處的聲明，包括當前和未來臨牀試驗的啓動、時間、進展和結果，Oculis 的研究和開發計劃，監管和商業戰略；預期里程碑；關於市場機會的聲明；以及關於現金流和資本需求的聲明，均為前瞻性聲明。所有前瞻性聲明均基於估計和假設，儘管 Oculis 及其管理層認為這些假設合理，但本質上是不確定的，並且本質上受到許多超出 Oculis 控制的風險、變數和意外情況的影響。這些前瞻性聲明僅供説明目的，並不打算作為投資者的保證、保證、預測或事實或概率的明確聲明。實際事件和情況難以或不可能預測，並將與假設不同。所有前瞻性聲明均受到風險、不確定性和其他因素的影響，這些因素可能導致實際結果與我們預期的結果和/或這些前瞻性聲明所表達或暗示的結果有實質性差異。前瞻性聲明受到許多條件的限制，其中許多超出了 Oculis 的控制，包括在 Oculis 的 20-F 表格年報和任何其他提交給 SEC 的文件中列出的風險因素部分。這些文件的副本可在 SEC 網站 www.sec.gov 上獲得。Oculis 沒有義務在本發佈日期後更新這些聲明以進行修訂或更改，除非法律要求。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTROalU0TXlNME1ESTBNRFUzTWpZak1qRTRPVEF5TXc9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTROalU0TXlNME1ESTBNRFUzTWpZak1qRTRPVEF5TXc9PQ"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png"/></p>

<p>Oculis Holding AG（納斯達克代碼：OCS）宣佈，其管理層將在首席執行官 Dr. Riad Sherif 的帶領下，參加於 6 月 9 日在邁阿密舉行的第 47 屆高盛全球醫療健康會議的爐邊談話。公司將概述其晚期產品組合，重點介紹用於視神經炎的 Privosegtor 和用於乾眼症的 Licaminlimab</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 回答中查看更多來自 StockTitan 的信息。將 StockTitan 添加為首選來源 · 打開 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><p>Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference.</p>
<div class="lb-trans"><p>Oculis Holding AG（納斯達克：OCS；XICE：OCS）（“Oculis” 或 “公司”）是一家全球生物製藥公司，專注於解決神經眼科和眼科疾病的創新，滿足重大未滿足的醫療需求，今天宣佈 Oculis 管理層將參加第 47 屆高盛全球醫療保健會議的爐邊聊天。</p>
</div><p>The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: <strong>Privosegtor</strong>, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the <strong>PIONEER</strong> registrational program to address unmet needs for two optic neuropathies and to unlock a potential market opportunity of $7B+ in the U.S. alone, and <strong>Licaminlimab</strong>, a topical anti-TNFα being evaluated in the <strong>PREDICT-1</strong> registrational trial as the first genotype-based precision medicine in dry eye disease (DED).</p>
<div class="lb-trans"><p>公司將提供其創新的當前晚期產品組合的概述和更新。主要亮點包括：<strong>Privosegtor</strong>，一種新型神經保護候選藥物，已獲得美國食品藥品監督管理局（FDA）的突破性療法認證和歐洲藥品管理局（EMA）的優先藥物（PRIME）認證，用於視神經炎（ON），在 <strong>PIONEER</strong> 註冊項目中，旨在滿足兩種視神經病的未滿足需求，並在美國獨自解鎖超過 70 億美元的潛在市場機會，以及 <strong>Licaminlimab</strong>，一種局部抗 TNFα藥物，正在 <strong>PREDICT-1</strong> 註冊試驗中評估，作為乾眼病（DED）中首個基於基因型的精準醫學。</p>
</div><p>With a strong balance sheet and advanced pipeline, Oculis prepares to deliver several pivotal readouts with the current funding, focusing on fulfilling its mission to save sight and improve eye care with groundbreaking treatments.</p>
<div class="lb-trans"><p>憑藉強大的資產負債表和先進的產品管線，Oculis 準備在當前資金的支持下交付多個關鍵結果，專注於實現其拯救視力和改善眼科護理的使命，提供突破性治療。</p>
</div><p><strong>47th Annual Goldman Sachs Global Healthcare Conference</strong></p>
<div class="lb-trans"><p><strong>第 47 屆高盛全球醫療保健會議</strong></p>
</div><p>Date: June 9, 4:00pm ET</p>
<div class="lb-trans"><p>日期：6 月 9 日，東部時間下午 4:00</p>
</div><p>Location: Miami, FL</p>
<div class="lb-trans"><p>地點：佛羅里達州邁阿密</p>
</div><p>Format: Fireside chat</p>
<div class="lb-trans"><p>形式：爐邊聊天</p>
</div><p>Presenter: Dr. Riad Sherif, CEO</p>
<div class="lb-trans"><p>演講者：Riad Sherif 博士，首席執行官</p>
</div><p>Webcast link: Register here</p>
<div class="lb-trans"><p>網絡直播鏈接：在此註冊</p>
</div><p>The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.</p>
<div class="lb-trans"><p>公司將在會議期間提供一對一會議。感興趣的投資者應聯繫其各自的代表，向贊助機構請求會議。</p>
</div><p>Webcast links, when available, are posted to the Oculis website on the Events &amp; Presentations page under the Investors &amp; Media section.</p>
<div class="lb-trans"><p>網絡直播鏈接在可用時會發布在 Oculis 網站的投資者與媒體部分的活動與演示頁面上。</p>
</div><p><strong>-ENDS-</strong></p>
<div class="lb-trans"><p><strong>-結束-</strong></p>
</div><p><strong>About Oculis</strong></p>
<div class="lb-trans"><p><strong>關於 Oculis</strong></p>
</div><p>Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neurological diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.</p>
<div class="lb-trans"><p>Oculis 是一家全球生物製藥公司（納斯達克：OCS；XICE：OCS），專注於突破性創新，以解決神經眼科和眼科領域中重大未滿足的醫療需求。Oculis 的高度差異化的晚期臨牀管線專注於兩個核心產品候選藥物。Privosegtor 是 PIONEER 項目中的突破性神經保護候選藥物，該項目包括旨在支持視神經病（包括視神經炎（ON）和非動脈性前缺血性視神經病（NAION）治療註冊計劃的研究。Privosegtor 還具有在其他神經眼科和神經疾病中開發額外適應症的潛力。Licaminlimab 是一種新型局部抗 TNFα藥物，正在進行註冊試驗，並採用基因型基礎的方法開發，用於治療乾眼病（DED）患者。Oculis 總部位於瑞士，在美國、冰島和瑞士開展業務，由經驗豐富的管理團隊領導，擁有成功的業績記錄，並得到領先國際醫療投資者的支持。</p>
</div><p>For more information, please visit: www.oculis.com</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問：www.oculis.com</p>
</div><p><strong>Oculis Contacts</strong></p>
<div class="lb-trans"><p><strong>Oculis 聯繫方式</strong></p>
</div><p>Sylvia Cheung, CFO</p>
<div class="lb-trans"><p>Sylvia Cheung，首席財務官</p>
</div><p>sylvia.cheung@oculis.com</p>
<div class="lb-trans"><p>sylvia.cheung@oculis.com</p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投資者關係</strong></p>
</div><p>LifeSci Advisors</p>
<div class="lb-trans"><p>LifeSci Advisors</p>
</div><p>Corey Davis, Ph.D.</p>
<div class="lb-trans"><p>Corey Davis，博士</p>
</div><p>cdavis@lifesciadvisors.com</p>
<div class="lb-trans"><p>cdavis@lifesciadvisors.com</p>
</div><p><strong>Media Relations</strong></p>
<div class="lb-trans"><p><strong>媒體關係</strong></p>
</div><p>ICR Healthcare</p>
<div class="lb-trans"><p>ICR Healthcare</p>
</div><p>Amber Fennell / David Daley / Sean Leous</p>
<div class="lb-trans"><p>Amber Fennell / David Daley / Sean Leous</p>
</div><p>oculis@icrhealthcare.com</p>
<div class="lb-trans"><p>oculis@icrhealthcare.com</p>
</div><p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示聲明</strong></p>
</div><p>This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; expected milestones; statements about market opportunity; and statements about cash runway and capital needs, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明和信息。例如，關於公司產品候選藥物潛在益處的聲明，包括當前和未來臨牀試驗的啓動、時間、進展和結果，Oculis 的研究和開發計劃，監管和商業戰略；預期里程碑；關於市場機會的聲明；以及關於現金流和資本需求的聲明，均為前瞻性聲明。所有前瞻性聲明均基於估計和假設，儘管 Oculis 及其管理層認為這些假設合理，但本質上是不確定的，並且本質上受到許多超出 Oculis 控制的風險、變數和意外情況的影響。這些前瞻性聲明僅供説明目的，並不打算作為投資者的保證、保證、預測或事實或概率的明確聲明。實際事件和情況難以或不可能預測，並將與假設不同。所有前瞻性聲明均受到風險、不確定性和其他因素的影響，這些因素可能導致實際結果與我們預期的結果和/或這些前瞻性聲明所表達或暗示的結果有實質性差異。前瞻性聲明受到許多條件的限制，其中許多超出了 Oculis 的控制，包括在 Oculis 的 20-F 表格年報和任何其他提交給 SEC 的文件中列出的風險因素部分。這些文件的副本可在 SEC 網站 www.sec.gov 上獲得。Oculis 沒有義務在本發佈日期後更新這些聲明以進行修訂或更改，除非法律要求。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTROalU0TXlNME1ESTBNRFUzTWpZak1qRTRPVEF5TXc9PQ" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE4NjU4MyM0MDI0MDU3MjYjMjE4OTAyMw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png" alt="" original-src="https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png"/></p>

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference | OCS Stock News

StockTitan

Oculis 將在第 47 屆年度高盛全球醫療保健會議上發表演講 | OCS 股票新聞